Search the Community

Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery. Corbus Pharmaceuticals Holdings, Inc. announced today that it has licensed the exclusive worldwide rights to develop, manufacture and market drug candidates, which includes CRB-4001, a peripherally–restricted, CB1 inverse agonist targeting liver, lung, heart and kidney fibrotic diseases. Corbus Pharmaceuticals, 09/20/2018. (Also see Clinical Trials and Endocannabinoid System) This item was posted in the ISN Newsroom. Please che